Literature DB >> 18290742

Medical management of ankylosing spondylitis.

Alexander A Khalessi1, Bryan C Oh, Michael Y Wang.   

Abstract

In the following literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor-alpha blockade therapy. Response should occur within 6-12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18290742     DOI: 10.3171/FOC/2008/24/1/E4

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  3 in total

1.  Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.

Authors:  Yi Fang; Lu-jin Li; Rui Wang; Feng Huang; Hai-feng Song; Zhong-ming Tang; Yu-zhen Li; Hua-shi Guan; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

2.  Health-related quality of life in patients undergoing cervico-thoracic osteotomies for fixed cervico-thoracic kyphosis in patients with ankylosing spondylitis.

Authors:  Silviu Sabou; Hossein Mehdian; Dritan Pasku; Luca Boriani; Nasir A Quraishi
Journal:  Eur Spine J       Date:  2018-02-22       Impact factor: 3.134

Review 3.  Medical Treatment of Ankylosing Spondylitis.

Authors:  Kyoung-Ho Moon; Young-Tae Kim
Journal:  Hip Pelvis       Date:  2014-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.